Literature DB >> 31342533

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.

Yvonne Huber1, Daniel Pfirrmann2, Ines Gebhardt1, Christian Labenz1, Nadine Gehrke1, Beate K Straub3, Christian Ruckes4, Heike Bantel5, Eugenio Belda6, Karine Clément7, Diana J Leeming8, Morten A Karsdal8, Peter R Galle1, Perikles Simon2, Jörn M Schattenberg1.   

Abstract

BACKGROUND: Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS: To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis.
METHODS: Patients with histologically confirmed NAFLD underwent an 8-week, web-based, individualised exercise program that contained bidirectional feedback.
RESULTS: Forty-four patients entered the study and 41 completed the assigned training goal (93.2%). In the completer population, 8 weeks of individualised exercise increased the VO2peak by 12.2% compared to baseline (P < .001). ALT and AST decreased by 14.3% (P = .002) and 18.2% (P < .001) and remained at this level until follow-up 12 weeks after the intervention. Markers of inflammation including hsCRP, ferritin, and M30 decreased. In parallel, gut microbiota exhibited increased metagenomic richness (P < .05) and at the taxonomic levels Bacteroidetes and Euryarchaeota increased whereas Actinobacteria phylum decreased. Surrogate scores of steatosis and fibrosis including the fatty liver index (FLI), FiB-4, APRI and transient elastography showed significant reductions. In parallel, a marker of procollagen-3 turnover (PRO-C3) decreased while C4M2, reflecting type IV collagen, degradation increased suggesting beneficial hepatic fibrosis remodelling from exercise. Also, an enhancement in health-related quality of life was reported.
CONCLUSION: The current study underlines the plausibility and potential of an 8 week individualised web-based exercise program in NAFLD. Clinical trial number: NCT02526732.
© 2019 John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 31342533     DOI: 10.1111/apt.15427

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study.

Authors:  Itziar Abete; M Angeles Zulet; Nuria Perez-Diaz-Del-Campo; Bertha Araceli Marin-Alejandre; Irene Cantero; J Ignacio Monreal; Mariana Elorz; José Ignacio Herrero; Alberto Benito-Boillos; Jose I Riezu-Boj; Fermín I Milagro; Josep A Tur; J Alfredo Martinez
Journal:  Eur J Nutr       Date:  2021-01-20       Impact factor: 5.614

Review 2.  Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis.

Authors:  Jörn M Schattenberg
Journal:  Visc Med       Date:  2020-05-05

3.  The Gut Microbiome and Nonalcoholic Steatohepatitis.

Authors:  Jörn M Schattenberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-03

4.  The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.

Authors:  Wolf Peter Hofmann; Peter Buggisch; Lisa Schubert; Nektarios Dikopoulos; Jeannette Schwenzer; Marion Muche; Gisela Felten; Renate Heyne; Patrick Ingiliz; Anna Schmidt; Kerstin Stein; Heiner Wedemeyer; Thomas Berg; Johannes Wiegand; Frank Lammert; Stefan Zeuzem; Jörn M Schattenberg
Journal:  JHEP Rep       Date:  2020-08-04

Review 5.  Diet and exercise in NAFLD/NASH: Beyond the obvious.

Authors:  Georg Semmler; Christian Datz; Thomas Reiberger; Michael Trauner
Journal:  Liver Int       Date:  2021-08-21       Impact factor: 8.754

Review 6.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

7.  Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol.

Authors:  Christian Labenz; Jürgen H Prochaska; Yvonne Huber; Michael Nagel; Beate K Straub; Philipp Wild; Peter R Galle; Jörn M Schattenberg
Journal:  Hepatol Commun       Date:  2019-09-30

8.  Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis.

Authors:  Sven Haufe; Katharina L Hupa-Breier; Pauline Bayerle; Hedwig T Boeck; Simone Rolff; Thorben Sundermeier; Arno Kerling; Julian Eigendorf; Momme Kück; Alexander A Hanke; Ralf Ensslen; Lars Nachbar; Dirk Lauenstein; Dietmar Böthig; Denise Hilfiker-Kleiner; Meike Stiesch; Christoph Terkamp; Heiner Wedemeyer; Axel Haverich; Uwe Tegtbur
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

9.  Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review.

Authors:  Siôn A Parry; Leanne Hodson
Journal:  Adv Ther       Date:  2020-03-07       Impact factor: 3.845

Review 10.  Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  David Carneros; Guillermo López-Lluch; Matilde Bustos
Journal:  Nutrients       Date:  2020-11-12       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.